ArticleJournal of intercultural ethnopharmacology
Antigiardial effect of Anethum graveolens aqueous extract in children.
Article in Journal of intercultural ethnopharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 20 citations in OpenAlex.
- Phytoextracts Used in the Treatment of Cryptosporidiosis and Giardiasis: Current State.Acta parasitologica · 2026Review
- Crop Wild Relatives (CWRs) in the United Arab Emirates: Resources for Climate Resilience and Their Potential Medicinal Applications.Drug design, development and therapy · 2025Review
- The Effects of Commercially AvailableInfection and drug resistance · 2022Article
- Systematic review on medicinal plants used for the treatment ofSaudi journal of biological sciences · 2021Review
- Historical ethnobotanical review of medicinal plants used to treat children diseases in Romania (1860s-1970s).Journal of ethnobiology and ethnomedicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiardia lamblia is the most common intestinal parasite of humans identified worldwide. In spite of metronidazole (Met) is the most commonly used drug for the treatment of giardiasis in humans, low patient compliance and side-effects, especially in children encourage efforts to look for new and safe agent; many plants used in folk medicine thought to have antigiardial effect, Anethum graveolens (AG) (dill) is an annual herb cultivated in Iraq used both as a medicinal agent and as food spice. The aim of this study was to investigate the effect of aqueous extract (AE) of AG leave in the treatment of giardiasis, compared with that of standard drug Met. PATIENTS AND
methodsA prospective randomized clinical trial was carried out on 28 pediatric patients of both sexes with age of <1 year ranging from 3 to 11 months, who attend to outpatient private clinic in Baghdad for a period of 6 months from June 2013 to December 2013,Patients participate in this study were allocated into two groups Group A composed of 14 patients treated with Met 15 mg/kg 3 times a day for 5 days. Group B composed of 14 patients treated with AGAE 1 ml 3 times a day for 5 days. Stool samples were collected at 0 time before administration of treatment, after 5 days and after 14 days from starting the treatments to check the efficacy of treatment.
resultsAdministration of AGAE results in a significant decrease in incidence of G. lamblia after 5 days of treatment indicating the efficacy of AGAE in the treatment of giardiasis a result that is comparable to that of Met.
conclusionThis study showed that pediatric patients with giardiasis may benefit from 5 days treatment with AGAE administered as 1 ml 3 times daily, the improvement in the symptom with this herbal agent was comparable to the standard pharmacological agent Met; results showed that AG is safe and tolerable over treatment course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.